Evidence map›Paper›PMID 39090236›Full record

ArticleEuropean journal of human genetics : EJHG2024

Colorectal cancer risk stratification using a polygenic risk score in symptomatic primary care patients-a UK Biobank retrospective cohort study.

Bethan Mallabar-Rimmer, Samuel W D Merriel, Amy P Webster, Leigh Jackson, Andrew R Wood, Matthew Barclay, Jessica Tyrrell, Katherine S Ruth, Christina Thirlwell, Richard Oram and 3 more

Abstract read
In one paragraph

Article in European journal of human genetics : EJHG, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Bethan Mallabar-RimmerDepartment of Clinical and Biomedical Sciences, University of Exeter, Exeter, UK.ORCID 0009-0004-4345-8414
Samuel W D MerrielDivision of Population Health, Health Services Research & Primary Care, University of Manchester, Manchester, UK.ORCID 0000-0003-2919-9087
Amy P WebsterDepartment of Clinical and Biomedical Sciences, University of Exeter, Exeter, UK.
Leigh JacksonDepartment of Clinical and Biomedical Sciences, University of Exeter, Exeter, UK.ORCID 0000-0002-0260-5295
Andrew R WoodDepartment of Clinical and Biomedical Sciences, University of Exeter, Exeter, UK.
Matthew BarclayDepartment of Behavioural Science & Health, Institute of Epidemiology & Health Care, University College London, London, UK.
Jessica TyrrellDepartment of Clinical and Biomedical Sciences, University of Exeter, Exeter, UK.ORCID 0000-0002-9256-6065
Katherine S RuthDepartment of Clinical and Biomedical Sciences, University of Exeter, Exeter, UK.ORCID 0000-0003-4966-9170
Christina ThirlwellBristol Medical School, University of Bristol, Bristol, UK.
Richard OramDepartment of Clinical and Biomedical Sciences, University of Exeter, Exeter, UK.
Michael N WeedonDepartment of Clinical and Biomedical Sciences, University of Exeter, Exeter, UK.
Sarah E R BaileyDepartment of Health and Community Sciences, University of Exeter, Exeter, UK.
Harry D GreenDepartment of Clinical and Biomedical Sciences, University of Exeter, Exeter, UK. h.d.green@exeter.ac.uk.ORCID 0000-0002-5105-184X

Funding

Cancer Research UK (CRUK) EDDPJT-May22\100006
6 · The paper itself

Abstract

Colorectal cancer (CRC) is a leading cause of cancer mortality worldwide. Accurate cancer risk assessment approaches could increase rates of early CRC diagnosis, improve health outcomes for patients and reduce pressure on diagnostic services. The faecal immunochemical test (FIT) for blood in stool is widely used in primary care to identify symptomatic patients with likely CRC. However, there is a 6-16% noncompliance rate with FIT in clinic and ~90% of patients over the symptomatic 10 µg/g test threshold do not have CRC. A polygenic risk score (PRS) quantifies an individual's genetic risk of a condition based on many common variants. Existing PRS for CRC have so far been used to stratify asymptomatic populations. We conducted a retrospective cohort study of 50,387 UK Biobank participants with a CRC symptom in their primary care record at age 40+. A PRS based on 201 variants, 5 genetic principal components and 22 other risk factors and markers for CRC were assessed for association with CRC diagnosis within 2 years of first symptom presentation using logistic regression. Associated variables were included in an integrated risk model and trained in 80% of the cohort to predict CRC diagnosis within 2 years. An integrated risk model combining PRS, age, sex, and patient-reported symptoms was predictive of CRC development in a testing cohort (receiver operating characteristic area under the curve, ROCAUC: 0.76, 95% confidence interval: 0.71-0.81). This model has the potential to improve early diagnosis of CRC, particularly in cases of patient noncompliance with FIT.

Indexed as

Colorectal NeoplasmsMultifactorial InheritancePrimary Health CareAdultAgedBiological Specimen BanksEarly Detection of CancerFemaleGenetic Risk ScoreHumansMaleMiddle AgedRetrospective StudiesRisk AssessmentRisk FactorsUK Biobank

Identifiers

PMID39090236
PMCPMC11577060

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.